GC Biopharma announced on February 14 that its last year’s sales were 1.711 trillion won, up 11.3% from the previous year, based on consolidated financial statements. Operating profit for the same period was 81.3 billion won, up 10.3% year-on-year.

Net profit was 69.4 billion won.

Research and development (R&D) expenses increased by 31.0% year-on-year to 191.3 billion won.

The company explained, “Last year, we achieved our highest ever revenue thanks to the expansion of our global business and the growth of our consolidated subsidiaries such as GC Cell.”

By each sector for revenues, the company recorded 420.4 billion won in blood products, 256.4 billion won in vaccines, 377.7 billion won in prescription drugs, and 190.4 billion won in consumer healthcare. 

In the prescription drug sector, sales of the flagship product, Hunterase, increased considerably by more than 30%.

An official from GC Biopharma said, "We will continue to focus on improving profitability by reducing costs while expanding R&D investments to enter overseas businesses."

[WIKI KOREA=Cho Pil Hyun, Staff Reporter]

chop23@wikileaks-kr.org

Cho Pil Hyun, Staff Reporter 다른기사 보기

• facebook
• 트위터
• 카카오톡
• 네이버블로그
• 유튜브